# Orion Pharma

> Pharmaceuticals oncology pain treatment

Business model and tags: B2B, Publicly traded, Manufacturing, Multi-product, Pharma & life sciences, Sells to enterprises, Multi-site, International operations, Has production sites, Has warehouses, Has in-house R&D, Has a works council

## About Orion Pharma

Development manufacturing marketing of human and veterinary pharmaceuticals focusing on oncology, pain, neurological and respiratory diseases treatments.

## Key facts

- **Industry**: Pharmaceutical Manufacturing
- **Company size**: 1,001–5,000 employees
- **Headquarters**: Espoo, Uusimaa, United Kingdom
- **Revenue**: £146M – £1.2B (Tamtam estimate)
- **Website**: [orionpharma.com](https://www.orionpharma.com/)
- **LinkedIn**: [linkedin.com/company/orion-pharma](https://www.linkedin.com/company/orion-pharma)

## Orion Pharma account plan

Orion is a Finnish pharmaceutical group in human and veterinary medicines and APIs: EUR 1,889.5 million FY2025 net sales, about 4,000 people.

[Read the Orion Pharma account plan](https://www.tamtam.ai/c/orion-pharma/account-plan)

## Orion Pharma in the news

- [Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion](https://www.globenewswire.com/news-release/2026/01/14/3218689/0/en/Orion-updates-time-estimate-for-the-potential-related-to-the-annual-Nubeqa-net-sales-recorded-by-Orion.html) · globenewswire.com · Jan 14, 2026
  Orion expects its Nubeqa® product to exceed EUR 1 billion in annual net sales by the end of the decade, though timing is uncertain due to market and regulatory factors.
- [Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)](https://www.globenewswire.com/news-release/2026/01/13/3217926/0/en/orion-corporation-disclosure-under-chapter-9-section-10-of-the-securities-market-act-blackrock-inc.html) · globenewswire.com · Jan 13, 2026
  BlackRock decreased its stake in Orion Corporation below 5%, a Nordic pharma company specializing in oncology and pain with EUR 1.5 billion sales in 2024.
- ['Cambridge our Silicon Valley' says Orion Pharma as it unveils key opportunities](https://www.businessweekly.co.uk/posts/cambridge-our-silicon-valley-says-orion-pharma-as-it-unveils-key-opportunities) · businessweekly.co.uk · Oct 26, 2025
  Orion Pharma is expanding its biologics R&D in Cambridge, UK, recruiting top talent to complement its Finnish operations and support long-term innovation.

[See all 5 articles](https://www.tamtam.ai/c/orion-pharma/news)

## Orion Pharma at a glance

Orion Pharma is a B2B company in the Pharmaceutical Manufacturing industry, headquartered in Espoo, Uusimaa, United Kingdom.

Orion Pharma has 1,001–5,000 employees.

Orion Pharma's revenue is £146M – £1.2B (Tamtam estimate).

## Frequently asked questions about Orion Pharma

### What is Orion Pharma's revenue?

Tamtam estimates Orion Pharma's annual revenue at £146M – £1.2B.

### How many employees does Orion Pharma have?

Orion Pharma has 1,001–5,000 employees.

### Where is Orion Pharma headquartered?

Orion Pharma is headquartered in Espoo, Uusimaa, United Kingdom.

---

Company data compiled by Tamtam from public sources and Tamtam's own analysis. Figures marked as estimates are modelled, not reported.

Source: https://www.tamtam.ai/c/orion-pharma
